Paper33294147
Empagliflozin improves chronic hypercortisolism-induced abnormal myocardial structure and cardiac function in mice.
Zhang QQ and 6 others. Ther Adv Chronic Dis, 2020. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Empagliflozin improves chronic hypercortisolism-induced abnormal myocardial structure and cardiac function in mice. Papers, record 33294147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33294147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Empagliflozin improves chronic hypercortisolism-induced abnormal myocardial structure and cardiac function in mice.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27085585 | Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes. | Clin Ther | 2016 | https://conductscience.org/library/papers/27085585 | PubMed |
| 2 | 22807233 | Prevalence of oral glucocorticoid usage in the United States: a general population perspective. | Arthritis Care Res (Hoboken) | 2013 | https://conductscience.org/library/papers/22807233 | PubMed |
| 3 | 30868176 | Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. | Diabetologia | 2019 | https://conductscience.org/library/papers/30868176 | PubMed |
| 4 | 31912605 | Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). | Eur J Heart Fail | 2020 | https://conductscience.org/library/papers/31912605 | PubMed |
| 5 | 26378978 | Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26378978 | PubMed |
| 6 | 19933822 | Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome. | Eur J Endocrinol | 2010 | https://conductscience.org/library/papers/19933822 | PubMed |
| 7 | 27585437 | Apocynin influence on oxidative stress and cardiac remodeling of spontaneously hypertensive rats with diabetes mellitus. | Cardiovasc Diabetol | 2016 | https://conductscience.org/library/papers/27585437 | PubMed |
| 8 | 30710997 | SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. | Cardiovasc Diabetol | 2019 | https://conductscience.org/library/papers/30710997 | PubMed |
| 9 | 30062155 | Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. | JACC Basic Transl Sci | 2017 | https://conductscience.org/library/papers/30062155 | PubMed |
| 10 | 28428225 | Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. | Diabetes | 2017 | https://conductscience.org/library/papers/28428225 | PubMed |
| 11 | 22728347 | The burden of Cushing's disease: clinical and health-related quality of life aspects. | Eur J Endocrinol | 2012 | https://conductscience.org/library/papers/22728347 | PubMed |
| 12 | 18269563 | Assessment of left ventricular diastolic function and Tei index by tissue Doppler imaging in patients with Cushing's Syndrome. | Echocardiography | 2008 | https://conductscience.org/library/papers/18269563 | PubMed |
| 13 | 27289126 | CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. | Diabetes Care | 2016 | https://conductscience.org/library/papers/27289126 | PubMed |
| 14 | 25611208 | Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis. | Horm Metab Res | 2015 | https://conductscience.org/library/papers/25611208 | PubMed |
| 15 | 23327928 | Decreased autonomic modulation of heart rate and altered cardiac sympathovagal balance in patients with Cushing's syndrome: role of endogenous hypercortisolism. | Neuroendocrinology | 2013 | https://conductscience.org/library/papers/23327928 | PubMed |
| 16 | 22004909 | Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. | Eur J Endocrinol | 2012 | https://conductscience.org/library/papers/22004909 | PubMed |
| 17 | 30571233 | Angiotensin II Causes Biphasic STAT3 Activation Through TLR4 to Initiate Cardiac Remodeling. | Hypertension | 2018 | https://conductscience.org/library/papers/30571233 | PubMed |
| 18 | 21470280 | Specific electrocardiographic features associated with Cushing's disease. | Clin Endocrinol (Oxf) | 2011 | https://conductscience.org/library/papers/21470280 | PubMed |
| 19 | 32865377 | Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32865377 | PubMed |
| 20 | 28132924 | Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. | Free Radic Biol Med | 2017 | https://conductscience.org/library/papers/28132924 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42277628 | Chemokine-Guided Biomimetic Mn/Ce Nanozymes for Immunomodulation and Cardioprotection in Doxorubicin-Induced Cardiomyopathy. | Adv Healthc Mater | 2026 | https://conductscience.org/library/papers/42277628 | PubMed |
| 42133559 | Potential Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Regulating Cardiac and Renal Fibrosis. | Cardiorenal Med | 2026 | https://conductscience.org/library/papers/42133559 | PubMed |
| 40542280 | Effects of SGLT2 ablation or inhibition on corticosterone secretion in high-fat-fed mice: exploring a nexus with cytokine levels. | Diabetologia | 2025 | https://conductscience.org/library/papers/40542280 | PubMed |
| 37691190 | Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial Hypertrophy. | Curr Drug Targets | 2023 | https://conductscience.org/library/papers/37691190 | PubMed |
| 37658280 | Sodium Glucose Transporter-2 Inhibitors (SGLT2Is)-TLRs Axis Modulates Diabetes. | Cell Biochem Biophys | 2023 | https://conductscience.org/library/papers/37658280 | PubMed |
| 37535237 | The anti-inflammatory and immunological properties of SGLT-2 inhibitors. | J Endocrinol Invest | 2023 | https://conductscience.org/library/papers/37535237 | PubMed |
| 36749400 | Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation. | Naunyn Schmiedebergs Arch Pharmacol | 2023 | https://conductscience.org/library/papers/36749400 | PubMed |
| 36232292 | Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36232292 | PubMed |
| 36110847 | Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications. | Front Immunol | 2022 | https://conductscience.org/library/papers/36110847 | PubMed |
| 35814223 | Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35814223 | PubMed |
| 35628443 | Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35628443 | PubMed |
| 35295328 | Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35295328 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| REN | 5972 | PubTator's text mining | https://conductscience.org/library/genes/5972 | NCBI Gene |
| SLC5A2 | 6524 | PubTator's text mining | https://conductscience.org/library/genes/6524 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33294147
GET https://conductscience.org/api/papers/v1/33294147/references?page=2